Genmab Reports Results of Darzalex (daratumumab) in P-III COLUMBA Study for Patients with R/R Multiple Myeloma
Shots:
- The P-III COLUMBA (NCT03277105) study involves assessing of Darzalex (SC) + recombinant human hyaluronidase PH20 (2000 U/mL) vs Darzalex (IV) in 522 patients with r/r multiple myeloma
- The P-III COLUMBA study results: ORR (41.1% vs 37.1%); geometric mean of Maximum Trough concentration (Ctrough) (499 mg/mL vs 463 mg/mL); no new safety signals
- Darzalex (daratumumab) is IgG1k mAb- with broad spectrum cytotoxic activity targeting CD38 and has received two BT designation from FDA as monothx & combination therapy. In Aug-2012 Janssen Biotech collaborated with Genmab to develop and commercialise daratumumab
Ref: Genmab | Image: Pharma News
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com